Willem-Jan Meijer appointed Chief Commercial Officer of DAB.bio

Delft, February 2024, DAB.bio has appointed Willem-Jan Meijer as Chief Commercial Officer. As of March 1st, he will be accountable for all commercial activities of the industrial biotech company and will be one of its two Managing Directors.Willem-Jan Meijer brings a wealth of competence and experience to DAB.bio, with a track record in investment banking, JV management, industrial commerce and licensing. His 28-year career includes roles with ING, Rabo, Synvina and Avantium. At Avantium, Willem-Jan was lastly responsible for Strategy and Licensing, which is at the core of DAB.bio’s commercial strategy.DAB.bio is a leader in industrial biotech. Its innovative FAST continuous fermentation platform dramatically reduces the production costs of biobased compounds and materials at industrial scale. The FAST technology combines its cost-advantaged manufacturing process with a wide application potential. As a result, many biomanufactured products can become cost-competitive with the same products made from fossil feedstock. The FAST technology promises to be an enabler for the fossil-to-biobased transition in several chemical value chains towards a net-zero future. DAB.bio recently signed development agreements with major German and American chemicals manufacturers.Eric van der Meer, DAB.bio CEO comments: “The Board and shareholders of DAB.bio are very pleased with the appointment of Willem-Jan Meijer. The company has enormous potential, and Willem-Jan brings excellent drive, energy, leadership and commercial insight. He is a valuable addition to the very strong technology team. We align very well in our vision to make DAB.bio a global agent for the much-needed transition to renewable biobased value chains. Willem-Jan’s contribution will be essential to deliver on that vision, and I am sure he will be very successful.”